Myasthenia gravis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Participants are eligible to be included in the study only if all the following criteria apply: 1. Type of Participant and Disease Characteristics Patients diagnosed definitively with MG, based on clinical presentations that align with national guidelines. 1)Muscle fatigability and weakness 2)Presence of anti-acetylcholine receptor (anti-AChR) or anti-muscle-specific kinase (anti-MuSK) antibodies 3)More than 10% decrement at repetitive nerve stimulation 4)Consistent improvement with anticholinesterase medications 2. For MG individuals co-infected with COVID-19, the COVID-19 diagnosis was determined according to previous study 1) Positive SARS-CoV-2 result obtained through real-time fluorescent PCR analysis of throat swab specimens 2) Positive COVID-19 antigen test or serology 3. Informed Consent 1) Participants who understand and agree to comply with planned study procedures 2) Capable of giving signed informed consent as described in protocol Supplementary Appendix Text 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion criteria
Exclusion criteria: 1) Cases with other definitive reasons accounted for MG worsening during this COVID-19 pandemic period were excluded. 2) The unclear diagnosis of both MG and COVID-19. 3) Failure to complete follow-up. 4) Unable to complete the associated questionnaires, comprehensive disease evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms of Myasthenia gravis exacerbation;MG-ADL score; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year mortality in myasthenia gravis patients; | — |
Countries
China
Contacts
The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine